210 related articles for article (PubMed ID: 33799686)
1. Prolyl Hydroxylase 3 Knockdown Accelerates
Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
[TBL] [Abstract][Full Text] [Related]
2. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
[TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
5. Decreased prolyl hydroxylase 3 mRNA expression in oncocytomas compared with clear cell renal cell carcinoma.
Kampantais S; Kounatidis I; Kotoula V; Vakalopoulos I; Gkagkalidis K; Dimitriadis G
Int J Biol Markers; 2020 Dec; 35(4):80-86. PubMed ID: 33118406
[TBL] [Abstract][Full Text] [Related]
6. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
7. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
8. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
9. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
11. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
13. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
Tanaka T; Torigoe T; Hirohashi Y; Sato E; Honma I; Kitamura H; Masumori N; Tsukamoto T; Sato N
J Cancer Res Clin Oncol; 2014 Mar; 140(3):503-13. PubMed ID: 24477694
[TBL] [Abstract][Full Text] [Related]
16. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
[TBL] [Abstract][Full Text] [Related]
17. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
19. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract][Full Text] [Related]
20. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
Salama MF; Carroll B; Adada M; Pulkoski-Gross M; Hannun YA; Obeid LM
FASEB J; 2015 Jul; 29(7):2803-13. PubMed ID: 25805832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]